AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-26. (canceled)

27. (currently amended) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody wherein said antibody is raised against a protofibril comprising an Aβ-Arc peptide comprising a mutation Glu₂₂-Gly₂₃ selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO: 1), and Aβ42-Arc (SEQ ID NO: 1).

28-31. (canceled)

- 32. (previously presented) The method according to claim 27, wherein said antibody is monoclonal.
- 33. (previously presented) The method according to claim 27, wherein said antibody is human or humanized.

34-43. (canceled)

44. (previously presented) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a protofibril comprising an $A\beta$ -Arc